1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HFHS 05-03, NCT00448240
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: DFCI-04006, AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF102988, NCT00424255
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1305, E1305, NCT00588770
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-3307-CC389, CASE-3307, CASE-CC389, CASE3307-CC389, NCT00608205
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-EGFr-203, NCT00401401
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCIRB #14735B, GV-001.010 (TNF-ELF), NCT00496236
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-069, NCT00570674
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15461, IND 102483, LBH589, NCT00738751
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 1516, NCT00815295
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SCCC-112008-019, 112008-019, ABX 236-HN08US, NCT00851877
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015580, NCT00841191
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-002-CRYO, NCT00861107
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: J08101, CA180123, NCT00882583
|
|
16.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 603EUSA03, NCT00901732
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VCC 0905, NCT00982436
|
|
18.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: J0916, NA_00023951, NCT01009346
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 09-131, NCT01016769
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: HSC-MS-04-259, NCT00178698
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0482, NCT00293579
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: OSI-3601S, Genentech, Inc., NCT00304278
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-26154 (GCC 0442), CA225092, NCT00343083
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06U.195, NCT00358007
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: PCI-05-087, 7440, NCT00407810
|
